PROCEPT BioRobotics Corporation Operating Lease, Expense
PROCEPT BioRobotics Corporation (PRCT) reported Operating Lease, Expense of $1.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-05
- PROCEPT BioRobotics Corporation operating lease, expense for the quarter ending 2026-06-30 was $1.00M, a 33.33% decline year-over-year.
- PROCEPT BioRobotics Corporation operating lease, expense for the quarter ending 2026-03-31 was $1.40M, a 12.50% decline year-over-year.
- PROCEPT BioRobotics Corporation operating lease, expense for the quarter ending 2025-09-30 was $1.80M, a 10.00% decline year-over-year.
- PROCEPT BioRobotics Corporation operating lease, expense for the quarter ending 2025-06-30 was $1.50M, a 16.67% decline year-over-year.
- PROCEPT BioRobotics Corporation operating lease, expense for fiscal 2023 was $8.40M, a 64.71% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation operating lease, expense for fiscal 2022 was $5.10M, a 88.89% increase from fiscal 2021.
- PROCEPT BioRobotics Corporation operating lease, expense for fiscal 2021 was $2.70M, a 6.90% decline from fiscal 2020.
- PROCEPT BioRobotics Corporation operating lease, expense for fiscal 2020 was $2.90M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-05 | $2.40M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $1.40M 10-Q · filed 2026-04-30 | |||
| 2025-09-30 | $1.80M 10-Q · filed 2025-11-05 | $3.30M derived: sum of 2 quarters · filed 2026-08-05 | $4.90M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.50M 10-Q · filed 2026-08-05 | $3.10M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $1.60M 10-Q · filed 2026-04-30 | |||
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-05 | $3.80M derived: sum of 2 quarters · filed 2025-11-05 | $5.40M 10-Q · filed 2025-11-05 | $7.20M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.80M 10-Q · filed 2025-08-07 | $3.40M 10-Q · filed 2025-08-07 | $5.20M derived: sum of 3 quarters · filed 2025-08-07 | $7.80M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.60M 10-Q · filed 2025-05-02 | $3.40M derived: sum of 2 quarters · filed 2025-05-02 | $6.00M derived: sum of 3 quarters · filed 2025-05-02 | $7.90M derived: sum of 4 quarters · filed 2025-05-02 |
| 2023-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $4.40M derived: sum of 2 quarters · filed 2024-10-28 | $6.30M derived: sum of 3 quarters · filed 2024-10-28 | $8.40M 10-K · filed 2024-02-28 |
| 2023-09-30 | $2.60M 10-Q · filed 2024-10-28 | $4.50M derived: sum of 2 quarters · filed 2024-10-28 | $6.60M 10-Q · filed 2024-10-28 | $8.30M derived: sum of 4 quarters · filed 2024-10-28 |
| 2023-06-30 | $1.90M 10-Q · filed 2024-08-02 | $4.00M 10-Q · filed 2024-08-02 | $5.70M derived: sum of 3 quarters · filed 2024-08-02 | $7.60M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $2.00M 10-Q · filed 2024-05-02 | $3.80M derived: sum of 2 quarters · filed 2024-05-02 | $5.70M derived: sum of 3 quarters · filed 2024-05-02 | $6.40M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $3.70M derived: sum of 2 quarters · filed 2024-02-28 | $4.40M derived: sum of 3 quarters · filed 2024-02-28 | $5.10M 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.90M 10-Q · filed 2023-11-02 | $2.60M derived: sum of 2 quarters · filed 2023-11-02 | $3.30M 10-Q · filed 2023-11-02 | $4.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $700.00K 10-Q · filed 2023-07-28 | $1.40M 10-Q · filed 2023-07-28 | $2.60M derived: sum of 3 quarters · filed 2024-02-28 | $3.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $700.00K 10-Q · filed 2023-05-04 | $1.90M derived: sum of 2 quarters · filed 2024-02-28 | $2.40M derived: sum of 3 quarters · filed 2024-02-28 | $3.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.70M derived: sum of 2 quarters · filed 2024-02-28 | $2.40M derived: sum of 3 quarters · filed 2024-02-28 | $2.70M 10-K · filed 2024-02-28 |
| 2021-09-30 | $500.00K 10-Q · filed 2022-11-04 | $1.20M derived: sum of 2 quarters · filed 2022-11-04 | $1.50M 10-Q · filed 2022-11-04 | $3.30M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $700.00K 10-Q · filed 2022-08-05 | $1.30M 10-Q · filed 2022-08-05 | $2.80M derived: sum of 3 quarters · filed 2022-08-05 | $3.30M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $700.00K 10-Q · filed 2022-05-06 | $2.10M derived: sum of 2 quarters · filed 2022-05-06 | $2.60M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $1.90M derived: sum of 2 quarters · filed 2022-03-22 | $2.90M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $500.00K 10-Q · filed 2021-11-05 | $1.50M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |